Washington HB 1728: Reauthorizing and amending dates for the total cost of insulin work group.

Bill Text

AN ACT Relating to reauthorizing and amending dates for the total 1
cost of insulin work group; amending RCW 70.14.160; creating a new 2
section; and providing an expiration date.3
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:4
Sec. 1. RCW 70.14.160 and 2020 c 346 s 2 are each amended to 5
read as follows:6
(1) The total cost of insulin work group is established. The work 7
group membership must consist of the insurance commissioner or 8
designee and the following members appointed by the governor:9
(a) A representative from the prescription drug purchasing 10
consortium described in RCW 70.14.060;11
(b) A representative from the pharmacy quality assurance 12
commission;13
(c) A representative from an association representing independent 14
pharmacies;15
(d) A representative from an association representing chain 16
pharmacies;17
(e) A representative from each health carrier offering at least 18
one health plan in a commercial market in the state;19
(f) A representative from each health carrier offering at least 20
one health plan to state or public school employees in the state;21
Z-0347.1
HOUSE BILL 1728
State of Washington 67th Legislature 2022 Regular Session
By Representatives Maycumber, Cody, Callan, Eslick, Macri, Ramos,
Griffey, Riccelli, and Leavitt; by request of Health Care Authority
Prefiled 01/03/22. Read first time 01/10/22. Referred to Committee
on Health Care & Wellness.
p. 1 HB 1728

(g) A representative from an association representing health 1
carriers;2
(h) A representative from the public employees' benefits board or 3
the school employees' benefits board;4
(i) A representative from the health care authority;5
(j) A representative from a pharmacy benefit manager that 6
contracts with state purchasers;7
(k) A representative from a drug distributor or wholesaler that 8
distributes or sells insulin in the state;9
(l) A representative from a state agency that purchases health 10
care services and drugs for a selected population;11
(m) A representative from the attorney general's office with 12
expertise in prescription drug purchasing; and13
(n) A representative from an organization representing diabetes 14
patients who is living with diabetes.15
(2) The work group must review and design strategies to reduce 16
the cost of and total expenditures on insulin in this state. 17
Strategies the work group must consider include, but are not limited 18
to, a state agency becoming a licensed drug wholesaler, a state 19
agency becoming a registered pharmacy benefit manager, and a state 20
agency purchasing prescription drugs on behalf of the state directly 21
from other states or in coordination with other states.22
(3) Staff support for the work group shall be provided by the 23
health care authority.24
(4) By December 1, ((2020)) 2022, the work group must submit a 25
preliminary report detailing strategies to reduce the cost of and 26
total expenditures on insulin for patients, health carriers, payers, 27
and the state. The work group must submit a final report by July 1, 28
((2021)) 2023, to the governor and the legislature. The final report 29
must include any statutory changes necessary to implement the 30
strategies.31
(5) This section expires December 1, ((2022)) 2024.32
NEW SECTION. Sec. 2. If specific funding for the purposes of 33
this act, referencing this act by bill or chapter number, is not 34
provided by June 30, 2022, in the omnibus appropriations act, this 35
act is null and void.36
--- END ---
p. 2 HB 1728